subject area of
- A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors Journal Articles
- Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma Journal Articles
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Journal Articles
- Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma Journal Articles
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies Journal Articles
- FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy Journal Articles
- Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data Journal Articles
- Immunotherapies in Dermatologic Disorders Journal Articles
- Immunotherapy in the Elderly Journal Articles
- Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology Journal Articles
- Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use Journal Articles
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Journal Articles
- Predictors of Immunotherapy-Induced Immune-Related Adverse Events Journal Articles
- SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma Conferences
- Targeted therapy for metastatic renal cell carcinoma Journal Articles
- The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population Journal Articles
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline Journal Articles
- Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients Journal Articles